Platinum‐containing chemotherapy leads to higher participants requiring chemotherapy delays compared with chemotherapy without platinum (high certainty).
Platinum‐containing chemotherapy leads to lower DFS at 2 years compared with chemotherapy without platinum (high certainty).
Platinum‐containing chemotherapy leads to lower OS at 2 years compared with chemotherapy without platinum (high certainty).
Platinum‐containing chemotherapy leads to lower OS at 5 years compared with chemotherapy without platinum (high certainty).
Platinum‐containing chemotherapy leads to higher pathological complete response compared with chemotherapy without platinum (high certainty).
Platinum‐containing chemotherapy leads to lower DFS at 2 years compared with chemotherapy without platinum (high certainty).
Platinum‐containing chemotherapy leads to lower OS at 2 years compared with chemotherapy without platinum (high certainty).
Platinum‐containing chemotherapy leads to lower OS at 5 years compared with chemotherapy without platinum (high certainty).
Hypofractionated radiation therapy showed no clear difference in local recurrence‐free survival (LR‐FS) at 10 years compared with conventionally fractionated radiation therapy (high certainty).
Hypofractionated radiation therapy showed no clear difference in cosmesis compared with conventionally fractionated radiation therapy (high certainty).
Hypofractionated radiation therapy showed no clear difference in mortality at 10 years compared with conventionally fractionated radiation therapy (high certainty).
Hypofractionated radiation therapy showed no clear difference in late subcutaneous toxicity compared with conventionally fractionated radiation therapy (high certainty).
Hypofractionated radiation therapy showed no clear difference in breast cancer‐specific survival (BC‐SS) at 10 years compared with conventionally fractionated radiation therapy (high certainty).
Hypofractionated radiation therapy showed no clear difference in relapse‐free survival (RFS) at 10 years compared with conventionally fractionated radiation therapy (moderate certainty).
The review found no eligible studies for this question.
High‐dose chemotherapy showed no clear difference in overall survival at 5‐year compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
High‐dose chemotherapy showed no clear difference in event‐free survival at 5‐year compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
High‐dose chemotherapy leads to higher treatment‐related mortality compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
High‐dose chemotherapy showed no clear difference in second cancers at 4 ‐ 9‐year median compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).